Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $20,000.00 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,000 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00. Following the sale, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $1,035,520. The trade was a 1.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $26,100.00.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock opened at $18.25 on Friday. The stock has a market cap of $965.42 million, a P/E ratio of -3.34 and a beta of 0.78. The stock’s fifty day moving average is $17.02 and its 200 day moving average is $16.20. Avalo Therapeutics, Inc. has a one year low of $6.57 and a one year high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. Analysts predict that Avalo Therapeutics, Inc. will post -2.58 EPS for the current year.

Institutional Trading of Avalo Therapeutics

Institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP raised its stake in Avalo Therapeutics by 806.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after purchasing an additional 510,540 shares during the period. DV Trading LLC bought a new stake in shares of Avalo Therapeutics during the first quarter valued at approximately $5,376,000. Glenmede Trust Co. NA raised its position in shares of Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock valued at $384,000 after buying an additional 5,280 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Avalo Therapeutics by 3.5% in the first quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after buying an additional 21,650 shares in the last quarter. Finally, Exome Asset Management LLC purchased a new position in shares of Avalo Therapeutics in the first quarter worth $2,379,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AVTX. Citizens Jmp reduced their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Bank of America assumed coverage on shares of Avalo Therapeutics in a report on Friday, June 12th. They set a “buy” rating and a $35.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Leerink Partners assumed coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target for the company. Finally, BTIG Research restated a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.80.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.